Abstract
In human, striatal dopamine content and number of nigrostriatal neurons are known to decline rapidly beyond the age of 45 years [1]. According to our present knowledge, the nigrostriatal dopaminergic neurons are the most rapidly aging neurons in the human brain. The dopamine content of the human caudate nucleus decreases enormously, by 13% per decade, over age 45. We know that symptoms of Parkinson’s disease (PD) appear if the dopamine content of the caudate sinks below 30% of the normal level. Thus, the normal aging of the system is slow enough so that the appearance of parkinsonian symptoms is not evident within the average lifespan. This is true for 99.9% of the human population. In 0.1%, however, the striatal dopaminergic system deteriorates rapidly. This small percentage of the population (see Figure 1) crosses the critical threshold and manifests the classical symptoms described by James Parkinson in 1817 in his famous book “Essay on the Shaking Palsy”. Parkinson’s disease (PD) may be regarded as a premature, rapid aging (of unknown origin) of the striatal dopaminergic machinery.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Birkmayer W., Riederer P. Parkinson’s disease: Biochemistry, clinical pathology and treatment. Wien: Springer Verlag, 1983: 194.
Martilla R. Epidemiological, clinical and virus-serological studies of Parkinson’s disease [thesis]. Reports from the Dept. of Neurology. Univ. of Turku, Finland 1974.
Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Molec. Pharmacol. 1978; 14: 333–343.
Mann DMA, Yates PO, Barton CM. Neuromelanin and RNA in cells of substantia nigra. J. Neuropathol. Exp. Neurol. 1977; 36: 379–83.
Graham DG. On the origin and significance of neuromelanin. Arch. Pathol. Lab. Med. 1979; 103: 359–62.
Munnel JF, Getty R. Rate of accumulation of cardiac lipofuscin in the aging canine. J. Gerontol. 1968; 23: 145–58.
Sohal RS, Donato H. Effect of experimental prolongation of life span on lipofuscin content and lyposomal enzyme activity in the brain of the housefly, Musca domestica. J. Gerontol. 1979; 34: 489–96.
Fridovich I. Superoxide dismutase. Advanc. Enzymol. 1974; 41: 35–97.
McCord JA, Fridovich I. Superoxide dismutase. An enzymic action of erythrocuprein (heamocuprein). J. Biol. Chem. 1969; 224: 6049–55.
Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 1972; 5: 393–08.
Knoll J. The possible mechanism of action of (—)-deprenyl in Parkinson’s disease. J. Neural Transm. 1978; 43: 177–98.
Cohen G, Pasik P, Cohen B, Leist A, Mytilineou G, Jahr MD. Pargyline and (-)- deprenyl prevent the neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. 1984; 106: 209–10.
Knoll J. The pharmacology of selective MAO inhibitors. In: Youdim MBH, Paykel ES, editors. Monoamine oxidase inhibitors. The state of the art. London: Wiley J, 1981: 45–61.
Knoll J. Selective inhibition of B-type monoamine oxidase in the brain: A drug strategy to improve the quality of life in senescence. In: Keverling-Buismann JA, editor. Strategy in drug research. Amsterdam: Elsevier, 1982: 107–35.
Knoll J. (—)-Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol. Scand. Suppl. 1983; 95: 57–80.
Knoll J. The facilitation of dopaminergic activity in the aged brain by (—)-deprenyl. A proposal for a strategy to improve the quality of life in senescence. Mech. Ageing. Dev. 1985; 30: 109–22.
Knoll J. Striatal dopamine, aging and (—) deprenyl. In: Borsy J, Kerecsen L, György L, editors. Dopamine, ageing and diseases. Budapest: Akadémiai Kiadó, New York: Perga- mon Press 1986: 7–26.
Harsing LG Jr, Magyar K, Tekes K, Vizi ES, Knoll J. Inhibition by (—)-deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine release inhibition. Pol. J. Pharmacol. Pharm. 1979; 31: 297–07.
Knoll J. Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Wolstenholme GES, Knight J, editors. Monoamine oxidase and its inhibition. Ciba foundation Symposium 39 (new series). Amsterdam: Elsevier 1976: 135–61.
Knoll J, Vizi ES, Somogyi G. Phenylisopropylmethylpropylamine (E-250), a monoamine oxidase inhibitor antagonizing the effects of tyramine. Arzneimittel-Forschung 1968; 18: 109–12.
Knoll J. On the dual nature of monoamine oxidase. Horizons Biochem. Biophys. 1978; 5: 37–64.
Knoll J. The pharmacology of selective irreversible monoamine oxidase inhibitors. In: Seiler N, Jung M, Koch-Weser J, editors. Enzyme-activated irreversible inhibitors. Amsterdam: Elsevier 1978: 253–69.
Knoll J. Monoamine oxidase inhibitors: chemistry and pharmacology. In: Sandler M, editor. Enzyme inhibitors as drugs. London: McMillan Press Ltd 1980: 151–71.
Blackwell B. Hypertensive crisis due to monoamine oxidase inhibitors. Lancet 1963; ii: 849–51.
Harsing LG Jr, Tekes K, Magyar K, Vizi ES, Knoll J. Deprenyl inhibits dopamine uptake in the rat striatum in vivo. In: Magyar K, editor. Monoamine oxidase and their selective inhibition. Budapest: Akadémiai Kiadó, New York: Pergamon Press 1979: 45–56.
Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, et al. (—)-Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacology 1978; 57: 33–78.
Sandler M, Glover V, Ashford A, Stern G. Absence of “cheese effect” during (—)- deprenyl therapy: some recent studies. J Neurol. Transm. 1978; 43: 209–14.
Knoll J. Critical role of MAO inhibition of Parkinson’s disease. Advances in Neurology 1986; 45: 107–10.
Knoll J. The pharmacology of (-)-deprenyl. J. Neurol. Transm. Suppl. 1986; 22: 75–89.
Abdorubo A, Knoll J. The effect of various MAO-B inhibitors on rabbit arterial strip response to tyramine. Pol. J. Pharmacol. Pharm. 1988; 40: 673–83.
Abdorubo A. The effect of various monoamine oxidase (MAO) inhibitors on the response of blood pressure of rats and cats to tyramine. Acta Physiol. Hung. 1990; 75: 321–346.
Knoll J. R-(—)-Deprenyl (Selegiline, MoverganR) facilitates the activity of the nigrostri- atal dopaminergic neuron. J. Neural. Transm., Suppl. 1987; 25: 45–66.
Knoll J. The striatal dopamine dependency of life span in male rats. Longevity study with (—)-deprenyl. Mech. Ageing Dev. 1988; 46: 237–62.
Knoll J. The pharmacology of selegiline ((—)-deprenyl). New aspects. Acta Neurol. Scand. 1989; 126: 83–91.
Knoll J. Nigrostriatal dopaminergic activity, (—)-deprenyl treatment, and longevity. Adv. Neurology 1990; 53: 425–9.
Carrillo MC, Kanai S, Nokubo M, Kitani K. (—)-Deprenyl induced activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci. 1991; 48: 517–21.
Misra HP, Fridovich J. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 1972; 247: 3170–75.
Beers RF Jr, Sizer IW. Spectrophotometry for measuring the breakdown of hydrogen peroxidase by catalase. J. Biol. Chem. 1952; 195: 133–40.
Knoll J. Medikamentöse Strategie zur Verbesserung der Lebensqualität in der Seneszenz. Wiener Med. Wschr, 1986; 136: [Suppl.] 3–18.
Knoll J. Role of B-type monoamine oxidase inhibition in the treatment of Parkinson’s disease. An uptake. In: Shah NS, Donald AG, editors. Movement disorders. New York: Plenum Press 1986: 53–81.
Kerecsen L, Kalász H, Knoll J. (—)-Deprenyl enhanced dopamine release from isolated striatal preparations of the rat following chronic treatment. In: Borsy J, Kerecsen L, György L, editors. Dopamine, ageing and diseases. Budapest: Akadémiai Kiadó, New York: Pergamon Press 1986: 27–33.
Zsilla G, Knoll J. The action of (—)-deprenyl on monoamine turnover rate in rat brain. Adv. Biochem. Psychopharmacol. 1982; 31: 211–17.
Zsilla G, Földi P, Held Gy, Székely AM, Knoll J. The effect of repeated doses of (—)-deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgy- line. Pol. J. Pharmacol. Pharm. 1986; 38: 57–67.
Knoll J, Yen TT, Dalló J. Long-lasting, true aphrodisiac effect of (—)-deprenyl in sexually sluggish old male rats. Mod. Probl. Pharmacopsychiat. 1983; 19: 135–53.
Knoll J. Some clinical implications of MAO-B inhibition. In: Yasuhara H, Parvez SH, Sandler M, Oguchi K, Nagatsu T, editors. Monoamine Oxidase: Basic and clinical aspects. Holland: VPS Press. In press.
Tariot PN, Cohen RM, Sunderland T. Newhouse PA, Yount D, Mellow AM, et at. l-Deprenyl in Alzheimer’s disease. Arch. Gen. Psychiatry 1987; 44: 427–433.
Tariot PN, Sunderland T, Weingartner H, Murphy DL, Welkovitz JA, Thompson K, et al. Cognitive effect of l-deprenyl in Alzheimer disease. Psychopharmacology 1987; 91: 489–95.
Tariot PN, Sunderland T, Cohen RM, Newhouse PA, Mueller EA, Murphy DL. Tranylcypromine compared with l-deprenyl in Alzheimer disease. J. Clin. Pschopharma- col. 1988; 8: 23–7.
Martini E, Pataky J, Szilágyi K, Venter V. Brief information on an early phase-II study with (—)-deprenyl in demented patients. Pharmacopsychiatry 1987; 20: 256–7.
Piccinin GL, Finali GC, Piccirilli M. Neuropsychological effects of l-deprenyl in Alzheimer’s type dementia. Clin. Neuropharmacol. 1990; 13: 147–63.
Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, et al. Effects of MAO-B inhibitor in the treatment of Alzheimer disease. Eur. Neurol. 1991; 31: 100–7.
Goad DL, Davis CM, Leim P, Fuselier CC, McCormack JR, Olsen KM. The use of selegiline in Alzheimer’s patients with behavior problems. J. Clin. Psychiatry 1991; 53: 342–45.
Milgram NW, Racine RJ, Nellis P, Mendoca A, Ivy G. Maintenance on l-deprenyl prolongs life in aged male rats. Life Sci. 1990; 47: 415–20.
Birkmayer W, Knoll J, Riederer P, Youdim MBH. (—)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson’s disease. Mod. Probl. Pharmacopsychiatry 1983; 19: 170–6.
Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J. Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson’s disease: a long-term study. J. Neural Transm. 1985; 64: 133–137.
Tetrud JW, Langston JW. The effect of (—)-deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989; 245: 519–22.
Parkinson Study Group. Effect of (—)-deprenyl in the progression of disability in early Parkinson’s disease. New England Journal of Medicine 1989; 321: 1364–71.
Tóth V, Kümmert M, Sugar J, Knoll J. A procedure for measuring neuromelanin in neurocytes by a TV-image analyser. Mech. Ageing Dev. 1992; 63: 215–221.
Knoll J, Tóth V, Kümmert M, Sugar J. (—)-Deprenyl and (—)-parafluorodeprenyl- treatment prevents age-related pigment changes in substantia nigra. A TV-image analysis of neuromelanin. Mech. Ageing Dev. 1992; 63: 157–163.
Rinne JO, Röyttä M, Paljärvi L, Rummukainen J, Rinne UK. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson’s disease. Neurology 1991; 41: 859–61.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Basel AG
About this chapter
Cite this chapter
Knoll, J. (1993). The Pharmacological Basis of the Therapeutic Effect of (—)-Deprenyl in Age-Related Neurological Diseases. In: Szelenyi, I. (eds) Inhibitors of Monoamine Oxidase B. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-6348-3_7
Download citation
DOI: https://doi.org/10.1007/978-3-0348-6348-3_7
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-6349-0
Online ISBN: 978-3-0348-6348-3
eBook Packages: Springer Book Archive